WHO declares Ebola emergency; U.S. bans travel

Good morning, healthcare professional.

The World Health Organization has declared the Ebola outbreak in Central Africa a public health emergency of international concern, prompting swift U.S. action including travel bans from Uganda, Congo, and South Sudan. Meanwhile, the Supreme Court delivered a landmark ruling upholding Medicare drug price negotiations, and Maryland became the first state to cap prices on Ozempic.

These developments signal a pivotal moment for both infectious disease response and pharmaceutical pricing policy. The Ebola declaration marks the first such emergency since COVID-19, while the court's decision removes the final legal barrier to government drug price negotiations affecting billions in healthcare spending.

In today's healthcare digest:

• WHO declares Ebola emergency as U.S. implements travel restrictions
• Supreme Court rejects pharmaceutical industry challenges to Medicare negotiations
• Maryland sets precedent with state-level price cap on Ozempic
• AstraZeneca secures multiple FDA approvals for hypertension and cancer drugs

WHO Declares Ebola Emergency as U.S. Responds with Travel Ban

The World Health Organization has declared the Ebola outbreak in Central Africa a public health emergency of international concern. The U.S. has responded by implementing travel bans from Uganda, Congo, and South Sudan, while health officials identify American patients with potential exposure.

Unpacked:

• The declaration marks the highest level of global health alert, triggered by the Bundibugyo strain spreading across multiple countries.
• U.S. officials have identified several Americans in Congo believed to have exposure to suspected cases.
• Experts debate deploying Merck's Ervebo vaccine, which isn't approved for this particular Ebola strain but may offer protection.

Supreme Court Upholds Medicare Drug Price Negotiations

The Supreme Court has declined to hear challenges from Novo Nordisk, AstraZeneca, and other pharmaceutical companies against Medicare drug price negotiation provisions in the Inflation Reduction Act. The decision solidifies the government's authority to negotiate prices for high-cost medications.

Unpacked:

• Multiple pharmaceutical manufacturers had challenged the IRA provisions as unconstitutional government overreach.
• The ruling removes the final legal obstacle to Medicare negotiations affecting the industry's most profitable products.
• Pharmaceutical companies must now adapt business models to accommodate government price controls on Medicare-covered drugs.

Maryland Becomes First State to Cap Ozempic Prices

Maryland's state affordability board has placed a price cap on Ozempic, marking the first state-level intervention on one of the pharmaceutical industry's most commercially successful medications. The decision sets a precedent for state action on high-cost drugs.

Unpacked:

• The affordability board determined Ozempic's current pricing creates excessive financial burden for state health programs.
• Maryland's action demonstrates growing state willingness to intervene in drug pricing independent of federal policy.
• Other states with affordability boards are expected to consider similar actions on GLP-1 medications.

AstraZeneca Secures Multiple FDA Approvals

AstraZeneca has received FDA approval for Baxfendy, a novel mechanism hypertension drug, while its partnership with Daiichi Sankyo secured dual FDA approvals for Enhertu in early breast cancer. The approvals expand treatment options in major therapeutic areas with substantial commercial potential.

Unpacked:

• Baxfendy represents the first new class of hypertension medication approved in over a decade.
• Enhertu's dual approvals for early breast cancer significantly expand the drug's eligible patient population.
• The approvals strengthen AstraZeneca's oncology and cardiovascular portfolios during a period of patent expirations.

The Shortlist

• Eli Lilly topped prominent rankings on pharmaceutical R&D performance, leading industry peers in innovation metrics.

• Novartis terminated its plant contract with Chinese CDMO Porton and is threatening $64 million in legal claims over manufacturing issues.

• Merck and China's Kelun scored positive results with their ADC candidate sac-TMT in a global endometrial cancer trial.

• Bristol Myers Squibb is considering Houston for a potential $1 billion manufacturing plant, according to recent filings.

• Regeneron's immunotherapy combination came up short in a melanoma trial, missing primary endpoints for the LAG-3 targeting approach.